Welcome to our dedicated page for BriaCell Therapeutics SEC filings (Ticker: BCTXZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BriaCell Therapeutics Corp. filings document the regulatory record of a British Columbia clinical-stage biotechnology company developing oncology immunotherapies. Registration statements and periodic disclosure materials cover capital structure, operating and financial results, governance matters, and securities issued by the company.
Recent filings also include Regulation FD reports furnishing BriaPro Therapeutics interim financial statements and management discussion, proxy materials for shareholder votes on directors, auditors and the omnibus equity incentive plan, and Form 25 disclosure addressing warrant listing and registration status on Nasdaq.